London-based drug development company Modern Biosciences (MBS) has appointed Kevin Moulder, formerly of GlaxoSmithKline (GSK), as its new head of development.
Moulder has spent over 18 years in leading UK and US pharmaceutical and biotechnology companies, most recently at drug discovery company Domantis where he was vice president of development.
In his new role, he will be responsible for day-to-day management of MBS" drug development effort. He will work with MBS" asset managers and chief scientific offer Dr Ian Wilding.
MBS ceo Dr Sam Williams, said: "We welcome Kevin to MBS. He brings extensive experience in managing drug development operations from large pharma to successful start-up biotechnology companies, all of which will be invaluable to MBS as we continue to build our portfolio of pre-clinical and Phase I drugs. Kevin's appointment adds to the recent recruitment of Will Turner, finance director, from IP Group plc and Lisa Patel, asset manager, from GSK."
